Showing 20 of 62 recruiting trials for “marginal-zone-lymphoma”
Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
RecruitingNCT06788652 ↗
A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
A Phase 2 Trial of Mosunetuzumab and Zanubrutinib for Patients With Relapsed/Refractory Marginal Zone Lymphoma
Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial
👨⚕️ Fei Li, professor, The First Affiliated Hospital of Nanchang University📍 1 site📅 Started Dec 2024View details ↗
Mosunetuzumab in Patients With Newly Diagnosed Extranodal Marginal Zone Lymphoma
Zanubrutinib Plus Rituximab as Front-line Treatment for Mucosa-associated Lymphoid Tissue Lymphoma (MALT)
Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma
Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)
PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas
👨⚕️ Shuhua Yi, Doctor, Institute of Hematology & Blood Diseases Hospital, China📍 1 site📅 Started Aug 2024View details ↗
RecruitingNCT06534463 ↗
Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)
Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas
Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local Therapy
👨⚕️ Bing Xu, The First Aiffiliated hosptical of xiamen University📍 1 site📅 Started Jun 2024View details ↗
DISCOVERY: Evaluating a Decision Support Tool for Adults Seen in Hematology/Oncology Clinics
👨⚕️ Daniel R Richardson, MD, MA, MSc, UNC Lineberger Comprehensive Cancer Center📍 1 site📅 Started Jun 2024View details ↗
Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
👨⚕️ Preetesh Jain, MBBS, MD, DM, PhD, M.D. Anderson Cancer Center📍 1 site📅 Started May 2024View details ↗
Zanubrutinib Plus Rituximab for Patients With Indolent Mantle Cell Lymphoma
Effects of Exercise Training in Survivors of Lymphoma
👨⚕️ Tormod S. Nilsen, PhD, Norwegian School of Sport Sciences📍 2 sites📅 Started Mar 2024View details ↗
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →